CardioVascular BioTherapeutics, Inc. (CVBT.PK) is a publicly traded company in the Unknown sector. Across all available filings, 1 corporate insiders have executed 45 transactions totaling $607.9K, demonstrating a bearish sentiment with -$607.9K in net insider flow. The most recent transaction on Jun 12, 2009 involved a sale of 100,000 shares valued at $20.0K.
No significant insider buying has been recorded for CVBT.PK in the recent period.
No significant insider selling has been recorded for CVBT.PK in the recent period.
Based on recent SEC filings, insider sentiment for CVBT.PK is bearish with an Insider Alignment Score of 0/100 and a net flow of -$607.9K. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at CardioVascular BioTherapeutics, Inc. (CVBT.PK) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 1 insiders are actively trading CVBT.PK stock, having executed 45 transactions in the past 90 days. The most active insider is Thomas Stegmann (Executive), who has made 45 transactions totaling $607.9K.
Get notified when executives and directors at CVBT.PK file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Jun 12, 2009 | Stegmann Thomas | Executive | Sale | 100,000 | $0.20 | $20.0K | |
| Jun 12, 2009 | Stegmann Thomas | Executive | Sale | 150,000 | $0.21 | $31.5K | |
| Jun 12, 2009 | Stegmann Thomas | Executive | Sale | 75,000 | $0.22 | $16.5K | |
| Jun 11, 2009 | Stegmann Thomas | Executive | Sale | 50,000 | $0.22 | $11.0K | |
| Jun 11, 2009 | Stegmann Thomas | Executive | Sale | 72,175 | $0.23 | $16.6K | |
| Jun 10, 2009 | Stegmann Thomas | Executive | Sale | 100,000 | $0.22 | $22.0K | |
| Jun 9, 2009 | Stegmann Thomas | Executive | Sale | 27,539 | $0.23 | $6.3K | |
| Jun 9, 2009 | Stegmann Thomas | Executive | Sale | 10,000 | $0.23 | $2.3K | |
| Jun 8, 2009 | Stegmann Thomas | Executive | Sale | 50,000 | $0.20 | $10.0K | |
| Jun 8, 2009 | Stegmann Thomas | Executive | Sale | 100,000 | $0.21 | $21.0K | |
| Jun 5, 2009 | Stegmann Thomas | Executive | Sale | 100,000 | $0.20 | $20.0K | |
| Jun 4, 2009 | Stegmann Thomas | Executive | Sale | 17,000 | $0.24 | $4.1K | |
| Jun 4, 2009 | Stegmann Thomas | Executive | Sale | 100,000 | $0.23 | $23.0K | |
| Jun 2, 2009 | Stegmann Thomas | Executive | Sale | 110,750 | $0.28 | $31.0K | |
| Jun 1, 2009 | Stegmann Thomas | Executive | Sale | 5,000 | $0.29 | $1.4K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 45 | $607.9K | 100.0% |
Insider selling pressure at CardioVascular BioTherapeutics, Inc. has increased, with 1 insiders executing 45 transactions across all time. Total sales of $607.9K significantly outpace purchases of $0, resulting in a net outflow of $607.9K. This selling activity appears largely discretionary, which may warrant closer attention from investors.